ROLE OF CARBOPLATIN IN OVARIAN-CANCER - CURRENT RESULTS AND THOUGHTS FOR THE FUTURE

被引：6

作者：

OZOLS, RF

机构：

来源：

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA | 1992年 / 71卷

关键词：

D O I：

10.1111/j.1600-0412.1992.tb00010.x

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Carboplatin is a cisplatin analog that causes less nephrotoxicity, neurotoxicity and nausea and vomiting than its parent compound. In prospective clinical trials, carboplatin has been shown to be as active, but less toxic, than cisplatin in previously untreated patients with advanced ovarian cancer. However, carboplatin has not led to improved survival, compared with cisplatin. Studies are in progress to reduce the dose-limiting myelosuppression of carboplatin in order to increase the dose intensity. In addition, new carboplatin combinations are also to be evaluated in clinical trials. The molecular basis for resistance to platinum compounds is also undergoing study and future clinical trials will evaluate modulations of resistance.

引用

收藏

页码：75 / 77

页数：3

相关论文

共 12 条

[1] RANDOMIZED PHASE-III TRIAL OF CHEMO-IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED STAGE-III AND STAGE-IV SUBOPTIMAL DISEASE OVARIAN-CANCER - A SOUTHWEST-ONCOLOGY-GROUP STUDY [J].

ALBERTS, DS ;

MASONLIDDIL, N ;

OTOOLE, RV ;

ABBOTT, TM ;

KRONMAL, R ;

HILGERS, RD ;

SURWIT, EA ;

EYRE, HJ ;

BAKER, LH .

GYNECOLOGIC ONCOLOGY, 1989, 32 (01) :8-15

[2]

Beltangady M, 1990, CARBOPLATIN JM 8 CUR, P175

[3] ADVANCED OVARIAN-CANCER - LONG-TERM RESULTS OF TREATMENT WITH INTENSIVE CISPLATIN-BASED CHEMOTHERAPY OF BRIEF DURATION [J].

HAINSWORTH, JD ;

GROSH, WW ;

BURNETT, LS ;

JONES, HW ;

WOLFF, SN ;

GRECO, FA .

ANNALS OF INTERNAL MEDICINE, 1988, 108 (02) :165-170

[4] AUGMENTATION OF ADRIAMYCIN, MELPHALAN, AND CISPLATIN CYTO-TOXICITY IN DRUG-RESISTANT AND DRUG-SENSITIVE HUMAN OVARIAN-CARCINOMA CELL-LINES BY BUTHIONINE SULFOXIMINE MEDIATED GLUTATHIONE DEPLETION [J].

HAMILTON, TC ;

WINKER, MA ;

LOUIE, KG ;

BATIST, G ;

BEHRENS, BC ;

TSURUO, T ;

GROTZINGER, KR ;

MCKOY, WM ;

YOUNG, RC ;

OZOLS, RF .

BIOCHEMICAL PHARMACOLOGY, 1985, 34 (14) :2583-2586

[5] ENHANCED DNA-REPAIR AND RESISTANCE TO CISPLATIN IN HUMAN OVARIAN-CANCER [J].

LAI, GM ;

OZOLS, RF ;

SMYTH, JF ;

YOUNG, RC ;

HAMILTON, TC .

BIOCHEMICAL PHARMACOLOGY, 1988, 37 (24) :4597-4600

[6] EFFECT OF GLUTATHIONE ON DNA-REPAIR IN CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELL-LINES [J].

LAI, GM ;

OZOLS, RF ;

YOUNG, RC ;

HAMILTON, TC .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (07) :535-539

[7] DOSE INTENSITY ANALYSIS OF CHEMOTHERAPY REGIMENS IN OVARIAN-CARCINOMA [J].

LEVIN, L ;

HRYNIUK, WM .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (05) :756-767

[8]

MASON JR, 1991, P AN M AM SOC CLIN, V10, P108

[9]

PATER J, 1990, P AN M AM SOC CLIN, V9, P155

[10] A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF CARBOPLATIN AND AUTOLOGOUS BONE-MARROW SUPPORT [J].

SHEA, TC ;

FLAHERTY, M ;

ELIAS, A ;

EDER, JP ;

ANTMAN, K ;

BEGG, C ;

SCHNIPPER, L ;

FREI, E ;

HENNER, WD .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (05) :651-661